TG Therapeutics, Inc. (TGTX) - Stock Analysis
Last updated: Jun 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin strength ⢠Cash burn ⢠Rising leverage TGTX has strong margins and liquidity, but negative cash flow, rising leverage, and a richer valuation make the stock less attractive despite reported earnings.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Strong breakout ⢠Pullback risk Support Level: $50.30â$51.50 Resistance Level: $53.22; no clear overhead resistance Over the last month, TGTX surged from $39.76 to $53.22 in a strong breakout, but the fast, extended move now raises near-term pullback risk toward $50 or the upper $40s if momentum cools.
Sentiment & News
Key News Insights: ⢠Guidance Raised ⢠Clinical Momentum ⢠Trial Expansion TG Therapeutics' strong BRIUMVI clinical readouts, expanded trial activity, and raised 2026 sales guidance point to accelerating commercial momentum despite recent share volatility.
AI Summary
TGTX has shifted from a speculative biotech story to a commercial execution story centered on BRIUMVI, but the key takeaway is that upside now depends on converting strong revenue growth and high margins into durable free cash flow while managing heavy product concentration, rising debt, and a stock that has already re-rated sharply.
Description
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes therapies for Bâcell malignancies and certain autoimmune disorders. Its pipeline combines monoclonal antibodies and oral small-molecule inhibitorsâtargeting Bâcell receptors and immune checkpointsâalongside early-stage programs in epigenetics and immune signaling, supported by multiple licensing and collaboration agreements with international partners. The company was incorporated in 1993 and is headquartered in New York, NY.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | TGTX | TG Therapeutics, Inc. | Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions. | Closed | +1.6% |